Abstracts tagged "COVID-19"

Abstract Number: L09 • ACR Convergence 2021
A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children
Matthew Clark¹, Danielle Rankin², Alisa Gotte¹, Alison Herndon¹, William McEachern¹, Andrew Smith³, Daniel Clark¹, Edward Hardison¹, Anna Patrick¹, Lauren Peetluk¹, Natasha Halasa¹, James Connelly¹ and Sophie Katz¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³The Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common infectious and…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: 0074 • ACR Convergence 2021
Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
David Yaich¹, Brandon Ptak¹, Emma Roellke¹, Erin Miller¹, Juliet Kim¹, Juan Gaztanaga¹, Wendy Drewes¹, James Ciancarelli², Jasmin Divers¹, Megan Winner¹, Amy Rapkiewicz¹ and Steven Carsons³, ¹NYU Langone Hospital - Long Island, Mineola, NY, ²NYU Hospital Hospital- Long Island, Mineola, NY, ³NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Critically ill patients with COVID-19 infection have a profound hypercoagulable state and can often develop thromboses in many different vascular beds. Given the presence…
Abstract Number: 0099 • ACR Convergence 2021
First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Kurt de Vlam¹, Jeroen Geldhof², Marie Truyens³, Joao Sabino⁴, Marc ferrante⁴, Jo Lambert³, Hilde lapeere³, Tom hillary⁴, an Van Laethem⁴, Triana Lobaton³, severine vermeire⁴, Barbara Neerinckx¹ and Patrick Verschueren⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²University Hospital Gent, Gent, Belgium, ³university hospital gent, gent, ⁴university hospitals leuven, leuven, ⁵University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
Abstract Number: 0119 • ACR Convergence 2021
Worsened Depression but Improved Fatigue Were the Main Impacts of Severe Lockdown in Non- COVID Infected Australian Fibromyalgia Patients
Benjamin Worcester¹, Emma Guymer² and Geoffrey Littlejohn², ¹Monash Health, Melbourne, Australia, ²Monash University, Melbourne, Australia
Background/Purpose: To gauge the impact of severe COVID-19 related lockdown restrictions on the mental and physical wellbeing of Australian fibromyalgia patients and their recovery following…
Abstract Number: 0618 • ACR Convergence 2021
Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
Alice Fike¹, Omer Pamuk², Yiming Luo³, Jun Chu⁴, Yanira Ruiz-Perdomo³, Sarfaraz Hasni³, Pravitt Gourh³ and James Katz⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²NIH/NIAMS, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The longitudinal experience of COVID-19 illness in patients with rheumatic diseases is emerging. Reports from the general population have described post-acute sequelae of SARS-CoV-2…
Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Caroline Diorio¹, Rawan Shraim¹, Laura Vella¹, Josephine Giles², Amy Baxter², Derek Oldridge², Scott Canna¹, Sarah Henrickson¹, Kevin Mcnerney¹, Frances Balamuth¹, Chakkapong Burudpakdee¹, Jessica Lee¹, Tomas Leng¹, Alvin Farrell¹, Michele Lambert¹, Kathleen Sullivan¹, John Wherry³, David Teachey¹, Hamid Bassiri¹ and Edward Behrens¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³UPenn, Philadelphia, PA
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…
Abstract Number: 1278 • ACR Convergence 2021
Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
Ariana González-Meléndez¹ and Luis Vilá², ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: The coronavirus disease 2019 (COVID-19) pandemic is of particular concern for people with autoimmune rheumatic diseases and for those who are immunosuppressed given the…
Abstract Number: 1536 • ACR Convergence 2021
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
Sara Tedeschi¹, Jack Ellrodt¹, Jacklyn Stratton¹, Leah Santacroce¹, Paulette Chandler¹, Ellen Gravallese² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
Abstract Number: 1554 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Valeria Valerio¹, Emmanouil Rampakakis², Marie Hudson³, Sasha Bernatsky³, Elizabeth M. Hazel³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²JSS Medical Research, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
Abstract Number: 1595 • ACR Convergence 2021
Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, Cristina Drenkard¹, Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim² and C. Barrett Bowling³, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Duke University, Durham, NC
Background/Purpose: Opportunities for community mobility, which reflects both physical mobility and social participation, during the COVID-19 pandemic have been limited and may have been related…
Abstract Number: 1613 • ACR Convergence 2021
Pandemic and Patients: Examining Health-Related Behaviors of Patients with Systemic Sclerosis During the COVID-19 Pandemic
Nancy Dorr¹, Patricia Fennell² and Lee Shapiro³, ¹The College of Saint Rose, Albany, NY, ²Albany Health Management Associates, Inc. Steffens Scleroderma Foundation, Albany, NY, ³Albany Medical College, Stillwater, NY
Background/Purpose: Prior to COVID-19, few studies examined how patients with a chronic illness, such as systemic sclerosis (SSc), react to a pandemic. This study examined…
Abstract Number: 1933 • ACR Convergence 2021
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Emily Gilbert⁵, Maria Valenzuela-Almada⁶, Leanna Wise⁷, Jeffrey Sparks⁸, Tiffany Hsu⁹, Kristin D'Silva¹⁰, Naomi Patel¹⁰, Emily Sirotich¹¹, Jean Liew¹², Jonathan Hausmann¹³, Paul Sufka¹⁴, Rebecca Grainger¹⁵, Suleman Bhana¹⁶, Wendy Costello¹⁷, Zachary Wallace¹⁸, Lindsay Jacobsohn¹⁹, Anja Strangfeld²⁰, Elsa Frazão Mateus²¹, Kimme Hyrich²², Laure Gossec²³, Loreto Carmona²⁴, Saskia Lawson-Tovey²², Lianne Kearsley-Fleet²⁵, Martin Schaefer²⁶, Pedro Machado²⁷, Philip Robinson²⁸, Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Jacksonville, FL, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Boston University, Boston, MA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁴HealthPartners, Eagan, MN, ¹⁵University of Otago, Wellington, New Zealand, ¹⁶Crystal Run Health, Montvale, NJ, ¹⁷Irish Children's Arthritis Network, Bansha, Ireland, ¹⁸Massachusetts General Hospital, Newton, MA, ¹⁹University of California San Francisco, Antioch, CA, ²⁰Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ²²University of Manchester, Manchester, United Kingdom, ²³Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²⁴Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ²⁵Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²⁶German Rheumatism Research Center, Berlin, Germany, ²⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²⁸Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].